JAMES ATKINS, M.D.
To the editor: In a recent article Winston and colleagues (1) describe their study as a "prospectively randomized, controlled study." Several of their points seem to need additional comments. First, with regard to the patient characteristics, why were the numbers of patients in the treatment and control groups with acute myelogenous (p =0.18) and acute lymphocytic leukemia (p =0.01) so different? What would be the effect of removing the patients with acute lymphocytic leukemia from the analysis? Did the fact that one group had more acute lymphocytic leukemia patients give that group a response advantage or disadvantage? These questions also
ATKINS J. Granulocyte Transfusion. Ann Intern Med. ;98:114. doi: 10.7326/0003-4819-98-1-114_1
Download citation file:
Published: Ann Intern Med. 1983;98(1):114.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use